专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明申请

WO2007090125A3 PROGNOSTIC FACTORS FOR ANTI-HYPERPROLIFERATIVE DISEASE GENE THERAPY 审中-公开
公开(公告)号：WO2007090125A3
公开(公告)日：2007-08-09
申请号：PCT/US2007/061320
申请日：2007-01-30
申请人： INTROGEN THERAPEUTICS, INC. , SOBOL, Robert, E. , CHADA, Sunil , ZUMSTEIN, Louis , CVITKOVIC, Esteban , MANANDER, Kerstin
发明人： SOBOL, Robert, E. , CHADA, Sunil , ZUMSTEIN, Louis , CVITKOVIC, Esteban , MANANDER, Kerstin
IPC分类号： G01N33/50 , G01N33/574
摘要： The present invention relates to the identification of various prognostic factors that predict response in patients with hyperproliferative disease such as cancer to gene therapy, and their use in methods of treating such patients with an anti-hyperproliferative disease gene therapy. Also described are methods of treatment for Li Fraumeni syndrome, and for assessing anti-cancer gene therapy using PET scans.

2. 发明申请

WO2016156905A1 PHARMACEUTICAL DOSES FOR A BROMODOMAIN AND EXTRATERMINAL PROTEIN (BET) INHIBITOR 审中-公开
标题翻译：溴化物和外源蛋白（BET）抑制剂的药物用量
公开(公告)号：WO2016156905A1
公开(公告)日：2016-10-06
申请号：PCT/IB2015/000624
申请日：2015-04-03
申请人： ONCOETHIX GMBH , CVITKOVIC, Esteban , HERAIT, Patrice
发明人： CVITKOVIC, Esteban , HERAIT, Patrice
IPC分类号： A61K31/5517 , A61P35/00 , A61P35/02
CPC分类号： A61K31/551 , A61P35/00 , A61P35/02
摘要： The invention is a method for treating patients with cancer comprising administering to the patient a safe and effective dose of (S)-2-(4-(4-chlorophenyl)-2,3,9- trimethyl-6H-thieno[3,2-f][1,2,4]triazolo[4,3-a][1,4]diazepin-6-yl)-N-(4- hydroxyphenyl)acetamideor a pharmaceutically acceptable salt or hydrate thereof, wherein the dose is between about 40 mg once per per day and about 120 mg once per per day. In one embodiment of the invention, the dose is about 40 mg once per per day, about 80 mg once per day or about 120 mg once per per day. In another embodiment of the invention, the dose is about 40 mg once per day. In another embodiment of the invention, the dose is about 80 mg once per day. In another embodiment of the invention, the dose is about 120 mg once per day. In another embodiment of the invention, the cancer is acute leukemia, older adult hematologic malignancy, lymphoma or multiple myeloma. In another embodiment of the invention, the lymphoma is diffuse large B-cell lymphoma.
摘要翻译：本发明是治疗癌症患者的方法，包括向患者施用安全有效剂量的（S）-2-（4-（4-氯苯基）-2,3,9-三甲基-6H-噻吩并[ 2-f] [1,2,4]三唑并[4,3-a] [1,4]二氮杂-6-基）-N-（4-羟基苯基）乙酰胺或其药学上可接受的盐或水合物，每天约40mg一次，每天约120mg一次。在本发明的一个实施方案中，剂量为每天约40mg一次，每天约80mg一次或每天一次约120mg。在本发明的另一个实施方案中，每天约40mg剂量。在本发明的另一个实施方案中，每天约80mg剂量。在本发明的另一个实施方案中，剂量为约120mg，每天一次。在本发明的另一个实施方案中，癌症是急性白血病，老年成人血液恶性肿瘤，淋巴瘤或多发性骨髓瘤。在本发明的另一个实施方案中，淋巴瘤是弥漫性大B细胞淋巴瘤。

3. 发明申请

WO2012131079A1 COMPOUNDS INHIBITING GALECTIN-1 EXPRESSION, CANCER CELL PROLIFERATION, INVASION, AND TUMORIGENESIS 审中-公开
标题翻译：化合物抑制GALECTIN-1表达，癌细胞增殖，入侵和肿瘤发生
公开(公告)号：WO2012131079A1
公开(公告)日：2012-10-04
申请号：PCT/EP2012/055902
申请日：2012-03-30
申请人： ONCOETHIX , RAYMOND, Eric , ASTORGUES-XERRI, Lucile , FAIVRE, Sandrine , CVITKOVIC, Esteban
发明人： RAYMOND, Eric , ASTORGUES-XERRI, Lucile , FAIVRE, Sandrine , CVITKOVIC, Esteban
IPC分类号： A61K31/00 , A61K31/165 , A61P35/00
CPC分类号： A61K31/165 , A61K31/00 , A61K45/06 , A61K2300/00
摘要： Disclosed herein are compositions comprising a galectin-1-targeting compound in a therapeutically effective composition for treating cancer. In an aspect, a galectin-1-targeting compound is OTX-008. Also disclosed herein are methods of making and using such compositions.
摘要翻译：本文公开了包含用于治疗癌症的治疗有效组合物中的半乳凝素-1-靶向化合物的组合物。一方面，半乳凝素-1-靶向化合物是OTX-008。本文还公开了制备和使用这些组合物的方法。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式